| Project/Area Number |
18K08585
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Hiroshima University (2023)
Department of Clinical Research, National Hospital Organization Kure Medical Center (2018-2022) |
|---|
Principal Investigator |
Shigematsu Hideo 広島大学, 原爆放射線医科学研究所, 講師 (40543707)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
尾崎 慎治 独立行政法人国立病院機構(呉医療センター臨床研究部), その他部局等, その他 (10558266)
|
|---|
| Project Period (FY) |
2018-04-01 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | Breast Cancer / Peritumoral edema / Neoadjuvant chemotherapy / Relapse free survival / Overall survival / 術前薬物療法 / 乳癌 / 腫瘍微小環境 / dormancy / 乳房浮腫 / 腫瘍免疫 / 非切除療法 / breast cancer / non operation |
|---|
| Outline of Final Research Achievements |
To elucidate the mechanism of dormancy induction by breast cancer drug therapy, we investigated the correlation between tumor microenvironment factors and prognosis in early-stage breast cancer patients treated with neoadjuvant chemotherapy. Focusing on peritumoral edema (PE) as a key microenvironmental factor, we conducted clinical and basic research. Among 128 early-stage breast cancer cases treated with neoadjuvant chemotherapy, 64 were positive for PE, with residual PE observed in 22 cases. Residual PE was identified as a significant adverse prognostic factor for recurrence-free survival and overall survival. Furthermore, an increased tendency of tumor-associated immune cells was noted in cancers with residual PE. These findings suggest that PE may serve as an adverse prognostic marker and a potential therapeutic target in early-stage breast cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
早期乳癌に対する術前化学療法は標準治療として施行される。術前化学療法後に病変遺残を認めた乳癌（no pCR）の予後は極めて不良であり、no pCR乳癌に対する治療戦略の開発は喫緊の課題である。本研究では術前化学療法が施行された乳癌を対象に乳房MRIにより腫瘍微小環境として腫瘍周囲浮腫（PE）を評価し、PE遺残が有意な予後不良因子であることを示した。PE遺残は腫瘍関連免疫細胞との相関が示唆され、腫瘍免疫細胞を標的とした治療がno pCR乳癌の予後改善に寄与することが期待される。本研究結果は、腫瘍微小環境を標的とした新たな治療戦略を提起し、no pCR乳癌の予後改善に寄与することが期待される。
|
